Alzamend Neuro
Manufacturing · Georgia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3480 Peachtree Rd NE Fl 2 Ste 103, Atlan...Phone Number
(844) 722-6333Website
www.alzamend.comRevenue
<$5 MillionStock Symbol
ALZNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Alzamend Neuro
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Explore more
Alzamend Neuro Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alzamend Neuro your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Alzamend Neuro has new funding data
Product Launch: Get notified when Alzamend Neuro launches new products
Congratulate Masked Content for being promoted to Masked Content at Alzamend Neuro
Alzamend Neuro, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Alzamend Neuro had a recent Job posting/layoffs
Check if Alzamend Neuro has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Alzamend Neuro is spiking on competitors!
Earning: See what the market has to say on Alzamend Neuro recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Alzamend Neuro as Masked Content
Find 3 more new buyers
Compare Similar Companies to Alzamend Neuro
Compare insights from companies similar to Alzamend Neuro, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alzamend Neuro is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alzamend Neuro is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alzamend Neuro.
Alzamend Neuro financials insights
Gather financial insights about Alzamend Neuro, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Share Placement
$10M
Stock Offering
$12.5M
2022
Private Equity
$4M
Alzamend Neuro Tech Stack
A closer look at the technologies used by Alzamend Neuro
See more technologies
Most Recent Scoops
Event
Milton Ault, Chairman and Founder, has appeared on a podcast called "Success Story with Scott D. Clary" on 07/01/2024. Topics discussed include Entrepreneurship, public markets, legal battles.
Project
Financial Planning
Event
Events
Event
Events
Project
Product Development
Alzamend Neuro News & Media
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001,...Alzamend Neuro director entity granted Series D preferred | ALZN Insider Trading
Ault Lending, LLC, controlled by Hyperscale Data, received 7,500 Series D preferred ALZN shares at $1,000 each. Each has $1,050 stated value and, at a $1.016 conversion price, was then convertible into about 1,033.5 common shares, plus existing warrant holdings.Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to support Alzamend's clinical programs and working capital needs ATLANTA,...Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alzamend Neuro
Sign Up For FreeTo access detailed company insights
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, pos... Read More
